

## COLIN LAW

Partner, Fangda Partners

+852 3749 1150  
colin.law@fangdalaw.com



### PRACTICE AREAS

**COLIN LAW** IS A PARTNER IN FANGDA'S HONG KONG OFFICE. HIS PRACTICE FOCUSES ON CAPITAL MARKETS AND SECURITIES TRANSACTIONS. HIS EXPERIENCE INCLUDES ADVISING BULGE BRACKET US INVESTMENT BANKS AND CHINESE COMPANIES ON INTERNATIONAL PUBLIC OFFERINGS, TAKEOVERS OF PUBLIC COMPANIES, PRIVATIZATION AND REGULATORY MATTERS. HE IS PARTICULARLY INVOLVED IN THE HEALTHCARE, BIOTECH AND MEDIA SECTORS.

HE REPRESENTS TOP-NOTCH INTERNATIONAL FINANCIAL INSTITUTIONS INCLUDING BANK OF AMERICA MERRILL LYNCH, CITIGROUP, GOLDMAN SACHS AND MORGAN STANLEY.

## REPRESENTATIVE MATTERS AND CASES

### Corporate Finance

- Jinxin Fertility Group Limited in its US \$400 million global offering and initial public offering on the Main Board of the HKEx
- Bank of America Merrill Lynch and Goldman Sachs as sponsors for the US \$205 million spin-off listing of Frontage, the US subsidiary of TigerMed
- Bank of America Merrill Lynch as sponsor and Morgan Stanley, Citigroup Global Capital Asia Limited and China International Capital Corporation as global coordinators in connection with the US \$200 million global offering of Koolearn Technology Holding Ltd. on the Main Board of the HKEx
- Morgan Stanley Asia Limited, Huatai Financial Holdings (Hong Kong) Limited and Goldman Sachs (Asia) L.L.C. as sponsors and global coordinators in the US\$1 billion global H-share offering of WuXi AppTech Co., Ltd on the Main Board of the HKEx

- Citigroup and CCB International Capital Limited as joint sponsors and joint global coordinators in connection with the US \$113 million global offering and initial public offering of Zhaoqing Kepei Education Group Limited on the Main Board of the HKEx
- Bank of America Merrill Lynch, Morgan Stanley and China Merchants Securities as sponsors in connection with the approximately US \$510 million global offering and initial public offering of WuXi Biologics (Cayman) Inc. on the Main Board of the HKEx
- Goldman Sachs (Asia) L.L.C., CLSA Limited, UBS AG, Hong Kong branch and Guotai Junan Securities (Hong Kong Limited) as underwriters in the HK \$900 million global offering of Hua Medicine on the Main Board of the HKEx, one of the first Chapter 18A IPOs in Hong Kong
- Jacobson Pharma Corporation Limited, a leading pharmaceutical company in Hong Kong, in its global offering and initial public offering on the Main Board of the HKEx
- Tianli Education International Holdings Limited in its HK \$1.73 billion (US \$220 million) global offering and initial public offering on the Main Board of the HKEx
- Bank of America Merrill Lynch and Morgan Stanley as sponsors in connection with the approximately US \$1.15 billion initial public offering (before the exercise of the over-allotment option) of Dali Foods Group Company Limited on the Main Board of the HKEx
- Citigroup Global Markets Asia Limited, Citigroup Global Markets Limited, CITIC CLSA Capital Markets Limited and CLSA Limited as joint global sponsors, joint global coordinators and joint lead managers in connection with the US \$88 million H-share initial public offering of Wenzhou Kangning Hospital Co., Ltd. on the Main Board of the HKEx
- Morgan Stanley, Goldman Sachs and China International Capital Corporation as the underwriters in connection with the approximately US \$248 million primary listing and global offering of IMAX China holding, Inc., a subsidiary of IMAX Corporation, on the Main Board of the HKEx
- Harmonicare Medical Holdings Limited, a private obstetrics and gynecology hospital group, in connection with its US \$205.1 million (HK \$1.59 billion) global offering and primary listing on the Main Board of the HKEx
- CGN Power Co., Ltd., the largest nuclear power producer in China, in connection with its US \$3.2 billion (US \$3.6 billion upon full exercise of over-allotment option) primary listing on the Main Board of the HKEx and global offering
- Fu Shou Yuan International Group Limited, a death care services provider in the PRC, in its US \$215 million primary listing and global offering of ordinary shares on the Main Board of the HKEx

- Future Land Development Holdings, a Chinese real estate developer, in connection with the HK \$2.06 billion (US \$265 million) Hong Kong initial public offering
- NASDAQ-listed Melco Crown Entertainment Limited for dual primary listing by way of introduction on the Main Board of the HKSE. The sponsors were Credit Suisse and Deutsche Bank
- GE China in obtaining an exemption from Hong Kong Securities and Futures Commission in relation to the documents disclosure requirement for the privatization of a public company
- The underwriters, led by CICC, Goldman Sachs, J.P. Morgan, Morgan Stanley, BOCI and Credit Suisse, in the US \$1.7 billion initial public offering, Rule 144A/Regulation S offering and Hong Kong Stock Exchange listing of the H shares of Changsha Zoomlion Heavy Industry Science and Technology Development Co., Ltd., a leading China-based construction machinery company
- Morgan Stanley and UBS as joint sponsors in the US \$850 million initial public offering of shares in Sihuan Pharmaceutical Holdings Group Ltd. on the Main Board of the HKEx
- Midas Holdings Limited, a Singapore-incorporated company, in its secondary listing on the HKEx. The Company is the leading manufacturer of aluminum alloy extrusion products for the passenger rail transportation sector in China. The deal raised approximately HK \$1.17 billion (before exercise of the over-allotment option) by way of a Hong Kong public offering and an international placing

## **M&A**

- Represented a consortium of investors including Ant Financials and JCDcaux in its offer for Clear Media (HKEx stock code:100) valued at approximately US \$500 million
- Advised Haier Electronics (HKEx stock code:1169) as an offeree in its response to an all-securities privatization offer by its parent Haier Smart Home (SHSE 600690)
- Represented WuXi Biologics (Cayman) Inc. (HKEx stock code: 2269) and its controlling shareholder in successive placing transactions, with an aggregate value over US \$5 billion
- Advised China Huaneng Group, a China SOE, on its potential acquisition of GCL New Energy (HKEx stock code : 0451), including advising on the potential mandatory general offer obligations under the Takeovers Code arising from the potential acquisition
- Advised KKR Asian Fund III L.P. on the acquisition of 70% interest in the China lighting business held by the Hong Kong-listed company NVC Lighting Holdings Limited, valuing the deal at US \$794 million

- Advised the Chairman of the TCL group regarding the general offer, acting in concert, disclosure of interests, dealings and director's duties implications arising from the restructuring of the TCL group involving TCL Corporation (Shenzhen Ex stock code: 000100), TCL Electronics Holdings Limited (HKEx stock code: 1070) and Tonly Electronics Holdings Limited (HKEx stock code: 1249), which resulted in a general offer being launched by TCL Industries Holdings Co., Ltd., which is owned by the Chairman, Suning.com Co., Ltd., Xiaomi Technology Co. Ltd., among others, for the shares in TCL Electronics Holdings Limited for HK \$4 billion and for the shares in Tonly Electronics Holdings Limited for HK \$1 billion
- Advised the largest independent shareholder of Hopewell Holding (HKEx stock code: 0054) in its privatization
- Advised a bidder seeking to acquire the fixed line network owned and operated by Hutchison Telecommunications Hong Kong Limited (HKEx stock code: 0215), which was finally sold to another bidder for HK \$14.5 billion
- Advised the controlling shareholder of Future Land Development Holdings Limited (HKEx stock code: 1030) in its privatization bid valued at US \$661 million
- Advised China Culiangwang Beverages Holdings Limited in connection with the US \$400.5 million disposal of its beverage business to Coca-Cola Beverages (Shanghai) Company Limited
- Advised Hung Hing Printing Group Limited on the sale of its subsidiary Sun Hing Paper Company Limited for US \$149 million, which was categorized as a very substantial disposal
- Advised Home Group Ltd on the sale of US \$53.4 million worth of its shares to Man Wah Holdings in return for a minority stake in Man Wah Holdings
- Advised Hong Kong-listed Shengmu Organic Milk Ltd. on the US \$335 million sale of its shares
- Advised Qatar Investment Authority, through wholly owned subsidiary Qatar Holdings LLC, in its acquisition of a 22% stake in CITIC Capital Holdings Limited
- Advised Hung Hing Printing Group Limited in its issue of US \$110 million in new shares to CVC Asia Pacific Limited and advised on the related Hong Kong Takeover Code implications
- Advised Shanghai Forte Land, a major property development company listed on the HKEx, in connection with a HK \$2,554 million privatization offer by Fosun International Limited

### **Regulatory**

- Advised Piper Jaffray on its acquisition and continued development of its Hong Kong investment banking arm and on related regulatory issues
- Advised GE China in obtaining an exemption from Hong Kong Securities and Futures Commission in relation to the documents disclosure requirement for the privatization of a public company

### **OTHER INFORMATION**

#### **Education**

- University of Hong Kong, PCLL
- University of Hong Kong, LL.B.

#### **Professional Qualification**

- Hong Kong, 1993
- England and Wales, 1997

#### **Languages**

English, Mandarin Chinese and Cantonese